Evidence map›Paper›PMID 35348200›Full record

Trial reportBritish journal of haematology2022

Activity and toxicity of intramuscular 1000 iu/m

Jasmeet Sidhu, Ashish Narayan Masurekar, Manash Pratim Gogoi, Caroline Fong, Tasos Ioannou, Taha Lodhi, Catriona Parker, Jizhong Liu, Amy A Kirkwood, Anthony V Moorman and 5 more

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Activity and toxicity of intramuscular 1000 iu/mBritish journal of haematology · 2022
    Trial
  2. Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Jasmeet SidhuTata Translational Cancer Research Centre, Tata Medical Center, Kolkata, India.ORCID 0000-0001-5926-5167
Ashish Narayan MasurekarChildrens Cancer Group, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Manash Pratim GogoiTata Translational Cancer Research Centre, Tata Medical Center, Kolkata, India.
Caroline FongChildrens Cancer Group, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Tasos IoannouChildrens Cancer Group, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Taha LodhiChildrens Cancer Group, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Catriona ParkerChildrens Cancer Group, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Jizhong LiuChildrens Cancer Group, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Amy A KirkwoodCancer Research UK & UCL Cancer Trials Centre, UCL Cancer Institute, University College, London, UK.
Anthony V MoormanWolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
Kiranmoy DasInterdisciplinary Statistical Research Unit, Indian Statistical Institute, Kolkata, India.
Nicholas J GouldenDepartment of Haematology, Great Ormond Street Hospital for Children, London, UK.
Ajay VoraDepartment of Haematology, Great Ormond Street Hospital for Children, London, UK.
Vaskar SahaTata Translational Cancer Research Centre, Tata Medical Center, Kolkata, India.ORCID 0000-0002-2916-9649
Shekhar KrishnanTata Translational Cancer Research Centre, Tata Medical Center, Kolkata, India.ORCID 0000-0002-6769-3847
University of Manchester · GBGreat Ormond Street Hospital · GBTata Medical Center · INCancer Research UK · GBIndian Statistical Institute · INNewcastle University · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

In successive UK clinical trials (UKALL 2003, UKALL 2011) for paediatric acute lymphoblastic leukaemia (ALL), polyethylene glycol-conjugated E. coli L-asparaginase (PEG-EcASNase) 1000 iu/m

Indexed as

Antineoplastic AgentsPrecursor Cell Lymphoblastic Leukemia-LymphomaAntibodiesAsparaginaseChildDrug MonitoringEscherichia coliHumansPolyethylene GlycolsAntibodiesAntineoplastic AgentsAsparaginasePolyethylene Glycolsacute lymphoblastic leukaemiachildrenPEG-asparaginase

Identifiers

PMID35348200
PMCPMC9314843
OpenAlexW4220923143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.